Prognostic value of melanoma-associated antigen A9 in renal cell carcinoma

References

• Lee CT, Katz J, Fearn PA, Russo P. Mode of presentation of renal cell carcinoma provides prognostic information. Urol Oncol 2002;7:135–40.
   PubMedGoogle Scholar
• Patard JJ, Leray E, Rodriguez A, Rioux-Leclercq N, Guille F, Lobel B. Correlation between symptom graduation, tumor characteristics and survival in renal cell carcinoma. Eur Urol 2003;44:226–32.
   PubMed Web of Science ®Google Scholar
• Hock LM, Lynch J, Balaji KC. Increasing incidence of all stages of kidney cancer in the last 2 decades in the United States: an analysis of surveillance, epidemiology and end results program data. J Urol 2002;167:57–60.
   PubMed Web of Science ®Google Scholar
• Mathew A, Devesa SS, Fraumeni JF. Jr, Chow WH. Global increases in kidney cancer incidence. 1973–1992. Eur J Cancer Prev 2002;11:171–8.
   PubMed Web of Science ®Google Scholar
• Lam JS, Leppert JT, Figlin RA, Belldegrun AS. Surveillance following radical or partial nephrectomy for renal cell carcinoma. Curr Urol Rep 2005;6:7–18.
   PubMedGoogle Scholar
• Ljungberg B, Cowan NC, Hanbury DC, Hora M, Kuczyk MA, Merseburger AS, et al. EAU guidelines on renal cell carcinoma: the 2010 update. Eur Urol 2010;58:398–406.
   PubMed Web of Science ®Google Scholar
• Kirkin AF, Dzhandzhugazyan KN, Zeuthen J. Cancer/testis antigens: structural and immunobiological properties. Cancer Invest 2002;20:222–36.
   PubMed Web of Science ®Google Scholar
• van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991;254:1643–7.
   PubMed Web of Science ®Google Scholar
• Gillespie AM, Coleman RE. The potential of melanoma antigen expression in cancer therapy. Cancer Treat Rev 1999;25:219–27.
   PubMed Web of Science ®Google Scholar
• Jungbluth AA, Busam KJ, Kolb D, Iversen K, Coplan K, Chen YT, et al. Expression of MAGE-antigens in normal tissues and cancer. Int J Cancer 2000;85:460–5.
   PubMed Web of Science ®Google Scholar
• De Plaen E, Arden K, Traversari C, Gaforio JJ, Szikora JP, De Smet C, et al. Structure, chromosomal localization, and expression of 12 genes of the MAGE family. Immunogenetics 1994;40:360–9.
   PubMed Web of Science ®Google Scholar
• Svobodova S, Browning J, Macgregor D, Pollara G, Scolyer RA, Murali R, et al. Cancer-testis antigen expression in primary cutaneous melanoma has independent prognostic value comparable to that of Breslow thickness, ulceration and mitotic rate. Eur J Cancer 2011;47:460–9.
   Google Scholar
• Shigematsu Y, Hanagiri T, Shiota H, Kuroda K, Baba T, Mizukami M, et al. Clinical significance of cancer/testis antigens expression in patients with non-small cell lung cancer. Lung Cancer 2010;68:105–10.
   PubMed Web of Science ®Google Scholar
• Melloni G, Ferreri AJ, Russo V, Gattinoni L, Arrigoni G, Ceresoli GL, et al. Prognostic significance of cancer-testis gene expression in resected non-small cell lung cancer patients. Oncol Rep 2004;12:145–51.
   PubMed Web of Science ®Google Scholar
• Ogata K, Aihara R, Mochiki E, Ogawa A, Yanai M, Toyomasu Y, et al. Clinical significance of melanoma antigen-encoding gene-1 (MAGE-1) expression and its correlation with poor prognosis in differentiated advanced gastric cancer. Ann Surg Oncol 2011;18:1195–203.
   Google Scholar
• Jeon CH, Shin IH, Park JB, Chae HD. Prognostic significance of MAGE in peritoneal washes in gastric carcinoma patients without peritoneal metastasis: results of a 5-year follow-up study. J Clin Gastroenterol 2010;44:682–6.
   Google Scholar
• Zhang S, Zhou X, Yu H, Yu Y. Expression of tumor-specific antigen MAGE, GAGE and BAGE in ovarian cancer tissues and cell lines. BMC Cancer 2010;10:163.
   PubMed Web of Science ®Google Scholar
• Pastorcic-Grgic M, Sarcevic B, Dosen D, Juretic A, Spagnoli GC, Grgic M. Prognostic value of MAGE-A and NY-ESO-1 expression in pharyngeal cancer. Head Neck 2010;32:1178–84.
   PubMed Web of Science ®Google Scholar
• Bergeron A, Picard V, LaRue H, Harel F, Hovington H, Lacombe L, et al. High frequency of MAGE-A4 and MAGE-A9 expression in high-risk bladder cancer. Int J Cancer 2009;125:1365–71.
   PubMed Web of Science ®Google Scholar
• Pitzer C, Stassar M, Zoller M. Identification of renal-cell-carcinoma-related cDNA clones by suppression subtractive hybridization. J Cancer Res Clin Oncol 1999;125:487–92.
   Google Scholar
• Oehlrich N, Devitt G, Linnebacher M, Schwitalle Y, Grosskinski S, Stevanovic S, et al. Generation of RAGE-1 and MAGE-9 peptide-specific cytotoxic T-lymphocyte lines for transfer in patients with renal cell carcinoma. Int J Cancer 2005;117:256–64.
   Web of Science ®Google Scholar
• Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 1982;6:655–63.
   PubMed Web of Science ®Google Scholar
• Macher-Goeppinger S, Aulmann S, Wagener N, Funke B, Tagscherer KE, Haferkamp A, et al. Decoy receptor 3 is a prognostic factor in renal cell cancer. Neoplasia 2008;10:1049–56.
   Google Scholar
• Picard V, Bergeron A, Larue H, Fradet Y. MAGE-A9 mRNA and protein expression in bladder cancer. Int J Cancer 2007;120:2170–7.
   Google Scholar
• Kocher T, Schultz-Thater E, Gudat F, Schaefer C, Casorati G, Juretic A, et al. Identification and intracellular location of MAGE-3 gene product. Cancer Res 1995;55:2236–9.
   Google Scholar
• Amar-Costesec A, Godelaine D, Stockert E, van der Bruggen P, Beaufay H, Chen YT. The tumor protein MAGE-1 is located in the cytosol of human melanoma cells. Biochem Biophys Res Commun 1994;204:710–15.
   Google Scholar
• Rimoldi D, Salvi S, Reed D, Coulie P, Jongeneel VC, De Plaen E, et al. cDNA and protein characterization of human MAGE-10. Int J Cancer 1999;82:901–7.
   PubMed Web of Science ®Google Scholar
• Jurk M, Kremmer E, Schwarz U, Forster R, Winnacker EL. MAGE-11 protein is highly conserved in higher organisms and located predominantly in the nucleus. Int J Cancer 1998;75:762–6.
   PubMedGoogle Scholar
• De Smet C, Lurquin C, Lethe B, Martelange V, Boon T. DNA methylation is the primary silencing mechanism for a set of germ line- and tumor-specific genes with a CpG-rich promoter. Mol Cell Biol 1999;19:7327–35.
   PubMed Web of Science ®Google Scholar
• Itoh K, Hayashi A, Nakao M, Hoshino T, Seki N, Shichijo S. Human tumor rejection antigens MAGE. J Biochem 1996;119:385–90.
   PubMedGoogle Scholar
• Sang M, Wang L, Ding C, Zhou X, Wang B, Lian Y, et al. Melanoma-associated antigen genes – an update. Cancer Lett 2011;302:85–90.
   PubMed Web of Science ®Google Scholar
• Morishima N, Nakanishi K, Takenouchi H, Shibata T, Yasuhiko Y. An endoplasmic reticulum stress-specific caspase cascade in apoptosis. Cytochrome c-independent activation of caspase-9 by caspase-12. J Biol Chem 2002;277:34287–94.
   PubMed Web of Science ®Google Scholar
• Yang B, O'Herrin SM, Wu J, Reagan-Shaw S, Ma Y, Bhat KM, et al. MAGE-A, mMage-b, and MAGE-C proteins form complexes with KAP1 and suppress p53-dependent apoptosis in MAGE-positive cell lines. Cancer Res 2007;67:9954–62.
   PubMed Web of Science ®Google Scholar
• Monte M, Simonatto M, Peche LY, Bublik DR, Gobessi S, Pierotti MA, et al. MAGE-A tumor antigens target p53 transactivation function through histone deacetylase recruitment and confer resistance to chemotherapeutic agents. Proc Natl Acad Sci USA 2006;103:11160–5.
   PubMed Web of Science ®Google Scholar
• Marcar L, Maclaine NJ, Hupp TR, Meek DW. Mage-A cancer/testis antigens inhibit p53 function by blocking its interaction with chromatin. Cancer Res 2010;70:10362–70.
   PubMedGoogle Scholar
• Traversari C, van der Bruggen P, Luescher IF, Lurquin C, Chomez P, Van Pel A, et al. A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J Exp Med 1992;176:1453–7.
   PubMed Web of Science ®Google Scholar
• van Baren N, Bonnet MC, Dreno B, Khammari A, Dorval T, Piperno-Neumann S, et al. Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells. J Clin Oncol 2005;23:9008–21.
   PubMed Web of Science ®Google Scholar
• Vantomme V, Dantinne C, Amrani N, Permanne P, Gheysen D, Bruck C, et al. Immunologic analysis of a phase I/II study of vaccination with MAGE-3 protein combined with the AS02B adjuvant in patients with MAGE-3-positive tumors. J Immunother 2004;27:124–35.
   PubMed Web of Science ®Google Scholar
• Corbiere V, Chapiro J, Stroobant V, Ma W, Lurquin C, Lethe B, et al. Antigen spreading contributes to MAGE vaccination-induced regression of melanoma metastases. Cancer Res 2011;71:1253–62.
   PubMed Web of Science ®Google Scholar
• Escudier B, Dorval T, Chaput N, Andre F, Caby MP, Novault S, et al. Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of the first phase I clinical trial. J Transl Med 2005;3:10.
   PubMed Web of Science ®Google Scholar
• Herbert N, Haferkamp A, Schmitz-Winnenthal HF, Zoller M. Concomitant tumor and autoantigen vaccination supports renal cell carcinoma rejection. J Immunol 2010;185:902–16.
   PubMed Web of Science ®Google Scholar
• Flanigan RC, Polcari AJ, Hugen CM. Prognostic variables and nomograms for renal cell carcinoma. Int J Urol 2011;18:20–31.
   PubMed Web of Science ®Google Scholar
• Kim HL, Seligson D, Liu X, Janzen N, Bui MH, Yu H, et al. Using tumor markers to predict the survival of patients with metastatic renal cell carcinoma. J Urol 2005;173:1496–501.
   PubMed Web of Science ®Google Scholar
• Kim HL, Seligson D, Liu X, Janzen N, Bui MH, Yu H, et al. Using protein expressions to predict survival in clear cell renal carcinoma. Clin Cancer Res 2004;10:5464–71.
   PubMed Web of Science ®Google Scholar
• Klatte T, Seligson DB, LaRochelle J, Shuch B, Said JW, Riggs SB, et al. Molecular signatures of localized clear cell renal cell carcinoma to predict disease-free survival after nephrectomy. Cancer Epidemiol Biomarkers Prev 2009;18:894–900.
   PubMed Web of Science ®Google Scholar